ANIK Director Gets 14,164 RSUs; Ownership Now 20,403 Shares

Insider transaction overview – Anika Therapeutics, Inc. (ANIK) On 20 June 2025, director Joseph H. Capper filed a Form 4 disclosing the award of 14,164 restricted stock units (RSUs) under transaction code “A” (award/grant).

Rhea-AI Filing Summary

Insider transaction overview – Anika Therapeutics, Inc. (ANIK)

On 20 June 2025, director Joseph H. Capper filed a Form 4 disclosing the award of 14,164 restricted stock units (RSUs) under transaction code “A” (award/grant). The grant was made at $0 cost; no open-market cash purchase occurred.

After the award, Capper’s total beneficial ownership rose to 20,403 common shares. The RSUs convert to common stock on a 1-for-1 basis and vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026, thereby tying compensation to medium-term company performance.

No derivative positions, sales, or additional acquisitions were reported, and the filing contains no financial performance data. The transaction appears to be a routine board-related equity grant that modestly strengthens alignment between the director and shareholders without signaling market sentiment through cash purchases.

Positive

• Beneficial ownership increases: Capper’s holdings climb to 20,403 shares, enhancing director–shareholder alignment.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine RSU grant; ownership rises to 20,403 shares—neutral market impact.

The Form 4 shows a standard non-cash equity award to director Joseph H. Capper. The 14,164 RSUs represent roughly two-thirds of his updated holdings, increasing skin-in-the-game but not involving an out-of-pocket purchase that would typically be interpreted as a bullish signal. Vesting through mid-2026 aligns board incentives with shareholder returns over the next year, yet the lack of open-market buying limits predictive value for near-term stock performance. Overall, the filing is informational and does not materially alter ANIK’s investment thesis.

Insider Trade Summary

Grant/Award: 14,164 shares

Grant/Award 1 txn

Insider Capper Joseph H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,164	$0.00	$0.00

Holdings After Transaction: Common Stock — 20,403 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANIK report on 20 June 2025?

Director Joseph H. Capper received 14,164 RSUs of Anika Therapeutics common stock.

At what price were the 14,164 RSUs granted to Joseph Capper?

The shares were granted at $0; no cash was exchanged.

When will Joseph Capper’s newly granted RSUs vest?

They vest on the earlier of the 2026 annual shareholder meeting or 20 June 2026.

How many ANIK shares does Joseph Capper now beneficially own?

Following the grant, he beneficially owns 20,403 common shares.

Does the Form 4 indicate any open-market buying or selling by the director?

No—this filing reports a routine RSU award; no open-market transactions were disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capper Joseph H

(Last) (First) (Middle)

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		14,164(1)	A	$0	20,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

	/s/ Joseph H. Capper	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.